Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Myelodysplastic Syndromes
NCT00565656Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jul 2007
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in myelodysplastic syndrome (MDS), sponsored by Centre Hospitalier Universitaire de Nice. Started Jul 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00565656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00565656.